DBV Technologies | DBVT - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 17.94M 17.86M 2025-09
BioCryst Pharmaceuticals USD 80.47M 15.39M 2024-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
DBV Technologies USD 3.63M 3.18M 2025-09
Esperion Therapeutics USD 39.98M 4.21M 2024-09
Galectin Therapeutics USD 1.48M 110K 2024-06
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12